Next Generation Sequencing Services Market by Type (Targeted, RNA, De Novo, WES, WGS), Technology (Sequencing by Synthesis, Ion Semiconductor, SMRT, Nanopore), Application (Research, Clinical [Oncology, Reproductive]), End User

Description

List of Tables

The Next Generation Sequencing (NGS) Services Market By Type (Targeted, RNA, De Novo, WES, WGS) Technology (Sequencing by Synthesis, Ion Semiconductor, SMRT, Nanopore) Application (Research, Clinical [Oncology, Reproductive]) End User-Global Forecast to 2030

The next generation sequencing services market is expected to grow at a CAGR of 19.9% from 2023 to 2030 to reach $20.39 billion by 2030. Following thorough secondary and primary research and in-depth analysis of the market scenario, the report discusses key industry drivers, restraints, challenges, and opportunities.

The growth of this market is mainly attributed to the reduced cost of NGS procedures, the development and approval of new targeted therapies, the rising prevalence of cancer, partnerships between NGS service providers and pharmaceutical companies, the high cost of sequencing infrastructure, and technological advancements in NGS. In addition, advancements in sequencing data analytics and the increasing applications of NGS in cancer and agri-genomics research are expected to offer significant growth opportunities for NGS service providers.

However, the availability of alternative technologies, lack of skilled professionals for sample preparation and analysis, and actionable mutations for precision medicine may restrain the growth of the NGS services market. Moreover, regulatory & standardization concerns in diagnostic testing and the ethical issues & costs related to non-invasive prenatal genetic testing are major challenges to the growth of this market.

Based on type, the global NGS services market is segmented into targeted sequencing services, whole-genome sequencing services, RNA sequencing services, exome sequencing services, de novo sequencing services, ChIP sequencing services, methyl sequencing services, and other NGS services. In 2023, the targeted sequencing services segment is estimated to account for the largest share of the global NGS services market. The large share of this segment can be attributed to the relatively lower cost, faster turnaround time, and accurate, easy-to-interpret results of targeted sequencing in the study of disease-related genes.

Based on technology, the global NGS services market is segmented into sequencing by synthesis, ion semiconductor sequencing, single-molecule real-time sequencing, nanopore sequencing, and DNA nanoball sequencing. In 2023, the sequencing by synthesis segment is estimated to account for the largest share of the global NGS services market. The large share of this segment is attributed to its highest yield of error-free throughput, base call value above Q30, and higher accuracy in DNA sequencing compared to other sequencing technologies available in the market.

Based on application, the global NGS services market is segmented into research applications and clinical applications. In 2023, the research applications segment is estimated to account for the largest share of the global NGS services market. This segment's large share is mainly attributed to the increasing demand for gene-based medicines, growing investments in drug research and development activities, and increasing research programs for personalized medicine.

Based on end user, the global NGS services market is segmented into hospitals & clinics, pharmaceutical & biotechnology companies, academic institutes & research centers, and other end users. In 2023, the hospitals & clinics segment is estimated to account for the largest share of the global NGS services market. The largest share of this segment is attributed to factors such as high capital requirements for building in-house NGS capabilities in hospitals & clinics, the rising prevalence of cancer and other chronic diseases, the growing demand for advanced medical treatments, and the rising number of biomarker-based therapies.

An in-depth analysis of the geographical scenario of the next generation sequencing services market provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. North America is expected to command the largest share of the global next generation sequencing services market in 2023, followed by Europe and Asia-Pacific.

Key companies operating in the global next generation sequencing services market are Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (U.S.), Eurofins Scientific S.E. (Luxembourg), Macrogen, Inc. (South Korea), LGC Limited (U.K.), GENEWIZ, Inc. (U.S.), Beijing Genomics Institute (China), MedGenome, Inc. (U.S.), DNA Link, Inc. (South Korea), Novogene Co., Ltd. (China), CD Genomics (U.S.), SeqLL, Inc. (U.S.), Otogenetics Corporation (U.S.), Foundation Medicine, Inc. (U.S.), Quest Diagnostics Incorporated (U.S.), and Invitae Corporation (U.S.).

Scope of the Report

Next Generation Sequencing Services Market Assessment-by Type

Targeted Sequencing Services
RNA Sequencing Services
De Novo Sequencing Services
Exome Sequencing Services
Chip Sequencing Services
Whole Genome Sequencing Services
Methyl Sequencing Services
Other Services

Next Generation Sequencing Services Market Assessment-Technology

Sequencing By Synthesis
Ion Semiconductor Sequencing
Single-molecule Real-time Sequencing
Nanopore Sequencing
DNA Nanoball Sequencing

Next generation Sequencing Services Market Assessment-Application

Research Applications
- Drug Discovery
- Agriculture & Animal Research
- Other Research Applications
Clinical Applications
- Reproductive Health Diagnosis
- Oncology
- Infectious Diseases
- Other Clinical Applications

(Other research applications include food microbiology, microbiota analysis in the beverage industry, and environmental studies, and other clinical applications include the detection of genetic aberrations in neurological disorders, rare diseases, metabolic and immune disorders, and food-borne illnesses)

Next Generation Sequencing Services Market Assessment-by End User

Hospitals & Diagnostic Laboratories
Pharmaceutical & Biotechnology Companies
Academic Institutes & Research Centers
Other End Users

Next Generation Sequencing Services Market Assessment-by Geography

North America
- U.S.
- Canada
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe (RoE)
Asia-Pacific (APAC)
- China
- Japan
- China
- India
- Rest of Asia Pacific (RoAPAC)
Latin America
Middle East & Africa

Product Code: MRHC - 104341

1. Introduction

1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders

2. Research Methodology

2.1. Research Approach
2.2. Process of Data Collection and Validation
- 2.2.1. Secondary Research
- 2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
2.3. Market Sizing and Forecasting
- 2.3.1. Market Size Estimation Approach
- 2.3.2. Growth Forecast Approach
- 2.3.3. Market Share Analysis
2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights

4.1. Overview
4.2. Factors Affecting Market Growth
- 4.2.1. Impact Analysis
- 4.2.2. Factor Analysis
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Buyers
- 4.3.2. Bargaining Power of Suppliers
- 4.3.3. Threat of Substitutes
- 4.3.4. Threat of New Entrants
- 4.3.5. Degree of Competition
4.4. Pricing Analysis
4.5. Regulatory Analysis
- 4.5.1. Overview
- 4.5.2. North America
  - 4.5.2.1. U.S.
  - 4.5.2.2. Canada
- 4.5.3. Europe
- 4.5.4. Asia-Pacific
  - 4.5.4.1. China
  - 4.5.4.2. Japan
  - 4.5.4.3. India
- 4.5.5. Latin America
- 4.5.6. Middle East
4.6. Industry & Technology Trends
- 4.6.1. Installation of In-house NGS Systems to Hinder Market Growth
- 4.6.2. Growing Utilization of NGS Services in Disease Diagnostics and Precision Medicine

5. NGS Services Market Assessment-by Type

5.1. Overview
5.2. Targeted Sequencing Services
5.3. RNA Sequencing Services
5.4. Whole Genome Sequencing Services
5.5. De Novo Sequencing Services
5.6. Exome Sequencing Services
5.7. ChIP Sequencing Services
5.8. Methyl Sequencing Services
5.9. Other NGS Services

6. NGS Services Market Assessment-by Technology

6.1. Overview
6.2. Sequencing by Synthesis
6.3. Ion Semiconductor Sequencing
6.4. Single-molecule Real-time Sequencing (SMRT)
6.5. Nanopore Sequencing
6.6. DNA Nanoball Sequencing

7. NGS Services Market Assessment-by Application

7.1. Overview
7.2. Research Applications
- 7.2.1. Drug Discovery
- 7.2.2. Agriculture & Animal Research
- 7.2.3. Other Research Applications
7.3. Clinical Applications
- 7.3.1. Oncology
- 7.3.2. Reproductive Health
- 7.3.3. Infectious Diseases
- 7.3.4. Other Clinical Applications

8. NGS Services Market Assessment-by End User

8.1. Overview
8.2. Hospitals and Diagnostic Laboratories
8.3. Pharmaceutical & Biotechnology Companies
8.4. Academic Institutes & Research Centers
8.5. Other End Users

9. NGS Services Market Assessment - by Geography

9.1. Overview
9.2. North America
- 9.2.1. U.S.
- 9.2.2. Canada
9.3. Europe
- 9.3.1. Germany
- 9.3.2. France
- 9.3.3. U.K.
- 9.3.4. Italy
- 9.3.5. Spain
- 9.3.6. Rest of Europe (RoE)
9.4. Asia-Pacific
- 9.4.1. China
- 9.4.2. Japan
- 9.4.3. India
- 9.4.4. Rest of Asia-Pacific (RoAPAC)
9.5. Latin America
9.6. Middle East & Africa

10. Competition Analysis

10.1. Overview
10.2. Key Growth Strategies
10.3. Competitive Benchmarking
10.4. Market Share Analysis (2022)
- 10.4.1. Eurofins Scientific S.E.
- 10.4.2. Illumina, Inc.
- 10.4.3. Foundation Medicine, Inc. (Subsidiary of F. Hoffmann-La Roche AG) (U.S.)
- 10.4.4. Invitae Corporation (U.S.)
- 10.4.5. Beijing Genomics Institute (BGI) (China)
- 10.4.6. Novogene Co., Ltd. (China)
- 10.4.7. Perkinelmer, Inc. (U.S.)
10.5. Competitive Dashboard
- 10.5.1. Industry Leaders
- 10.5.2. Market Differentiators
- 10.5.3. Vanguards
- 10.5.4. Emerging Companies

11. Company Profiles

11.1. Illumina, Inc.
11.2. Eurofins Scientific S.E.
11.3. Invitae Corporation
11.4. Foundation Medicine, Inc. (Subsidiary of F. Hoffmann-La Roche AG)
11.5. Beijing Genomics Institute (BGI)
11.6. Novogene Co., Ltd.
11.7. Perkinelmer, Inc.
11.8. Macrogen, Inc.
11.9. QIAGEN N.V.
11.10. LGC Limited
11.11. GENEWIZ, Inc. (Subsidiary of Azenta, Inc.)
11.12. MedGenome, Inc.
11.13. DNA Link, Inc.
11.14. CD Genomics
11.15. Otogenetics Corporation
11.16. Quest Diagnostics Incorporated

12. Appendix

12.1. Available Customization
12.2. Related Reports